Webinar Alert! Assessing the Use of Non-Human Primates in Translational Research Today Register Today!

IND-Enabling Bioanalysis for Non-Viral Vectors

PROVEN INTELLIGENCE IN NON-VIRAL VECTOR BIOANALYSIS.

Expert Bioanalytical Strategies for Non-Viral Vectors

CELL & GENE | RNA | BIOLOGICS

Executive Summary

Bioanalytical strategies for polymeric and hybrid non-viral vectors require a tailored approach that accounts for the unique physicochemical properties of these systems. A phase-appropriate assay development plan is necessary to characterize payload integrity, biodistribution, and immunogenicity, aligning with GxP principles for submissions to global regulatory bodies like the FDA, EMA, and Germany’s Paul-Ehrlich-Institut. Franklin Biolabs leverages a deep understanding of complex delivery systems to design and execute bioanalytical programs that support an 18-24 month timeline to IND.

A close-up of a scientist in blue gloves gently holding a small, white laboratory mouse, likely in a research setting.

Frequently Asked Questions

How do bioanalytical strategies for polymeric vectors differ from LNP-based RNA therapies?

While both are non-viral, polymeric vectors often present unique challenges in characterizing polydispersity and the stability of the polymer-payload complex. Bioanalytical assays must quantify not just the RNA payload but also the distribution and clearance of the polymer itself, as its properties can influence both efficacy and potential toxicity.

What are the key considerations for an Investigational Medicinal Product Dossier (IMPD) submission regarding non-viral vector biodistribution?

For IMPD submissions to European authorities, including Germany’s regulators, biodistribution data must be exceptionally robust. This includes quantitative assessment of payload delivery to the target tissue and a comprehensive evaluation of non-target tissue biodistribution. The data must be generated from well-controlled studies in relevant animal models to support the first-in-human dose selection.

How are GxP principles applied to phase-appropriate assay development for novel hybrid nanoparticles?

GxP principles are applied progressively. For early discovery, assays are qualified for purpose to ensure data is reliable for internal decision-making. As a program advances toward IND-enabling toxicology studies, key bioanalytical methods for PK, biodistribution, and immunogenicity are formally validated according to GxP standards to meet stringent regulatory requirements for data integrity and reproducibility.

A promotional graphic for Franklin BioLabs showcasing a list of their notable scientific publications in preclinical and translational research.

Phase-Appropriate Bioanalytical Characterization for Polymeric and Hybrid Vectors

The bioanalytical assessment of polymeric and hybrid non-viral vectors cannot rely on a standardized template. The inherent complexity of these systems – from polyplexes and ligand-targeted nanoparticles to inorganic delivery platforms – demands a bespoke strategy. Each vector’s unique composition, charge, size, and payload release kinetics directly influences its biological activity and safety profile.

Developing a robust data package requires a phase-appropriate approach to assay development. Our scientific team designs and validates methods that align with your program’s specific stage, ensuring the data generated is fit-for-purpose and compliant with global GxP expectations for IND, CTA, and IMPD submissions.

Key bioanalytical endpoints for these modalities include:

  • Payload Quantification & Integrity: Assays to confirm the stability of the therapeutic payload (e.g., mRNA, siRNA, gRNA) within the vector and after its release in biological matrices.

  • Vector Biodistribution: Quantitative methods (qPCR, LC-MS) to determine the tissue distribution and clearance of both the payload and the vector components.

  • Immunogenicity Assessment: Evaluation of innate and adaptive immune responses directed against the polymeric or hybrid components, which can impact both safety and therapeutic durability.

  • Pharmacodynamic Biomarkers: Measurement of target engagement and biological response in relevant tissues to establish a clear link between vector delivery and functional outcome.

Translating Non-Viral Delivery into Clinical Reality

The long-term clinical viability of non-viral systems has been demonstrated. A phase 2b trial using a gene-liposome complex showed that repeated administration could achieve a sustained, clinically meaningful effect over 12 months (PMID: 26149841). This underscores the need for a long-term bioanalytical strategy to monitor both efficacy and safety.

The route of administration is a variable that profoundly impacts biodistribution and safety outcomes, a principle that holds true across all next-generation therapies (PMID: 28806897). A bioanalytical plan must be designed to specifically address the intended clinical route, whether systemic, inhaled, or localized.

Our work is conducted within a >100,000 sq ft facility designed for advanced preclinical and bioanalytical services. While Franklin Biolabs was launched in 2024, our core scientific leadership and principal scientists maintain a 100% successful IND rate since 2019, a track record that informs every bioanalytical program we undertake. This deep experience, including our collaboration with Moderna on their LNP platform, provides the proven intelligence necessary to navigate the specific challenges of polymeric and hybrid vectors.

For a comprehensive overview of our capabilities, please see our parent hub page: Bioanalytical Services.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities